MIRAE ASSET
Mutual Fund

Mirae Asset Healthcare Fund

Sectoral / Thematic Fund - An open ended equity scheme investing in healthcare and allied sectors

Data as on 31st July 2026

INVEST IN POTENTIALLY HEALTHY FUND

Mirae Asset Mutual Fund -SEBI/MF/055/07/03

WHY HEALTHCARE FUND?

- Diversified Across the Pharma & Healthcare Sector
- Long Term Wealth Creation from a Multi Decade Theme
- An Evolving Theme with Significant Growth Potential
- Enormous Opportunities for Advancement

INVESTMENT FRAMEWORK

Flexibility to invest across market capitalisation and style in selecting investment opportunities within this theme

Endeavour to maintain a concentrated portfolio of 30–40 stocks, in sectors like hospitals, diagnostics, specialty chemicals, medical equipment, insurance and other allied sub sectors

The investment Framework stated above may change from time to time without any notice and shall be in accordance with the strategy as mentioned in the Scheme Information Document of the scheme. For Complete asset allocation and Investment Strategy, please refer Scheme Information Document of the fund: https://www.miraeassetmf.co.in/downloads/forms

TOP 10 STOCK HOLDING

Stocks	Jun 2026	Jul 2026
Sun Pharmaceutical Industries Ltd.	10.95%	11.06%
Divi's Laboratories Ltd.	7.53%	8.71%
Torrent Pharmaceuticals Ltd.	0.46%	7.47%
Apollo Hospitals Enterprise Ltd.	6.09%	5.94%
Glenmark Pharmaceuticals Ltd.	6.09%	5.53%
Laurus Labs Ltd.	4.61%	5.13%
Aurobindo Pharma Ltd.	4.33%	3.82%
Alkem Laboratories Ltd.	3.54%	3.56%
Fortis Healthcare Ltd.	3.80%	3.55%
Krishna Institute of Medical Sciences Ltd.	3.85%	3.48%

TOP 10 SECTOR HOLDINGS

Sectors	Jun 2026	Jul 2026
Pharmaceuticals & Biotechnology	74.93%	74.78%
Healthcare Services	23.77%	22.92%
Chemicals & Petrochemicals	1.08%	1.05%

MARKET CAPITALIZATION ^



PORTFOLIO PSYCHOGRAPHICS

Portfolio

Number of Stocks (Equity)	27
Top 10 Stock %	58.25%
Top 5 Sectors %	98.75%

Risk Ratios

Beta	0.94
Alpha	-1.09%
Portfolio Turnover Ratio	0.30 Times
Information Ratio	-0.25

FUND DETAILS

Fund Manager: Mr. Vrijesh Kasera (since July 02, 2018), Mr. Tanmay Mehta (since April 01, 2025)

SIP Amount:
Daily, Monthly and Quarterly: Minimum of ₹99/- (multiples of ₹1/- thereafter), minimum 5 in case of Daily / Monthly / Quarterly option.

Minimum Investment Amount: ₹5,000/- and in multiples of ₹1/- thereafter. Minimum Additional Application Amount: ₹1,000/- per application and in multiples of ₹1/- thereafter.

Plans and options: Regular Plan and Direct Plan with Growth Option and IDCW Option (Payout & Re-investment)

Allotment Date: 2^{nd} July 2018

Benchmark: BSE Healthcare Index (TRI)

Net AUM: ₹ 3,442.28 Cr.

IDEAL INVESTOR PROFILE

Goal: Aim for wealth creation

Investment Time Horizon: 5 years+

Risk Profile: Very High

#The sector(s)/stock(s)/issuer(s) mentioned in this presentation do not constitute any research report/recommendation of the same and the fund may or may not have any future position in these sector(s)/stock(s)/issuer(s). For complete portfolio of the scheme, please visit the website https://www.miraeassetmf.co.in/downloads/portfolio.
^Pursuant to Clause 3.9 of Part IV of the SEBI Master Circular dated March 20, 2026, the universe of 'Large Cap' shall consist of the top 100 entities, 'Mid Cap' shall consist of the 101st to 250th entities, and 'Small Cap' shall consist of the 251st and onwards entities in terms of full market capitalization.
For further information about other schemes (product labelling and performance of the fund) please visit the website of the AMC: www.miraeassetmf.co.in
For detailed AAUM disclosure, please visit: https://www.miraeassetmf.co.in/docs/default-source/other-disclosure/average-assets-under-management-(aaum)-disclosure-(monthly)-july-2026.xlsx

Distributed By

PRODUCT LABELLING

Mirae Asset Healthcare Fund

This product is suitable for investors who are seeking*

- To generate long term capital appreciation
- Investments in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sector in India

*Investors should consult their financial advisors if they are not clear about the suitability of the product.